SLC25A45

Across TCGA pan-cancer cohorts, SLC25A45 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SLC25A45’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC25A45 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC25A45 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, KICH, and KIRC are the cancer types where SLC25A45 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A45 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.114	<.001	11	view →
KICH	Male	III,IV	−1.077	<.001	9	view →
KIRC	Female	All	+0.620	<.001	9	view →
LIHC	All	III,IV	+0.891	<.001	8	view →
LUSC	All	All	−0.553	<.001	5	view →
ESCA	Female	All	+1.093	.026	2	view →
PRAD	All	All	+0.695	<.001	2	view →
BLCA	Male	IV	−0.595	.008	1	view →
COAD	Female	IV	−0.585	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SLC25A45–THCA

Open the THCA breakdown →